Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Nanobiotix Achieves Primary and Secondary Endpoints in Ph II/III Study in Soft Tissue Sarcoma with NBTXR3
Nanobiotix Achieves Primary and Secondary Endpoints in Ph II/III Study in Soft Tissue Sarcoma with NBTXR3
Nanobiotix Achieves Primary and Secondary Endpoints in Ph II/III Study in Soft Tissue Sarcoma with NBTXR3
Submitted by
CP Staff
on June 22, 2018 - 10:14am
Source:
CP Wire
News Tags:
Nanobiotix
NBTXR3
soft tissue sarcoma
Headline:
Nanobiotix Achieves Primary and Secondary Endpoints in Ph II/III Study in Soft Tissue Sarcoma with NBTXR3
snippet:
Primary endpoint was the pathological Complete Response Rate
The main secondary endpoint was the resection margin status evaluating the quality of surgery
NBTXR3 accumulates in tumors and is activated by radiation therapy
Do Not Allow Advertisers to Use My Personal information
